Odyssey Therapeutics, Inc.

Odyssey Therapeutics Inc is a United States-based biotechnology company. The Company operates as a clinical-stage biotechnology company that discovers and develops precision medicines for autoimmune, inflammatory diseases, and oncology. It also focuses on creating a pipeline of internally discovered product candidates. It uses a combination of deep biological computational tools, including artificial intelligence (AI) and machine learning (ML), to target difficult-to-drug pathways and create novel small molecule and protein therapeutics. Its diversified portfolio of programs, including OD-07656 (RIPK2 inhibitor), IRAK4 Scaffolding Inhibitor and TNFR2 Agonist and TSLP/IL-33 Antagonist.